title: Bypassing Bypass Surgery and Other Success Stories from the National Institutes of Health.
abstract: After a heart attack, patients often undergo a procedure to open up the clogged artery and install a tiny meshlike device called a stent to keep the artery propped open. In most cases, the body reacts to this foreign object with scar-tissue formation, and the artery narrows again. To combat this re-clogging process, National Institutes of Health inventors developed paclitaxel-coated stents and later licensed it to Angiotech. Approved by the Food and Drug Administration in March 2004, these stents are expected to substantially reduce the use of coronary artery bypass surgery, an expensive operation now performed annually on 350,000-plus Americans. This and three other examples of NIH licensing success stories are described in this paper: (a) Kepivance, which improves the quality of life for cancer patients by eliminating mouth sores, (b) AIDS drug ddI, an important component of many combination drug therapies, and (c) Vitravene, the first and only antisense drug to be approved by FDA. These four examples will illustrate the success not only of the NIH licensing program, but also the innovative approaches taken by NIH inventors and the persistence of its commercial partners. This paper also highlights the business and legal lessons learned from these four cases.
authors.affiliation: Postdoctoral fellow at the National Cancer Institute, however, she contributed to this work during a technology transfer fellowship at the National Institutes of Health in Bethesda, Maryland.
authors.forename: Ruchika
authors.initials: R
authors.lastname: Nijhara
authors.forename: J Lille
authors.initials: JL
authors.lastname: Tidwell
authors.forename: Steven
authors.initials: S
authors.lastname: Ferguson
authors.forename: Krishna
authors.initials: K
authors.lastname: Balakrishnan